EGFR and bone metastasis: As shown in Tables 2, 3, 431 (49.1%) patients in the EGFR mutation group developed metastasis, lung metastasis (166 cases, 18.9%, P = 0.004), brain metastasis (166 cases, 18.9%, P = 0.001) and bone metastasis (238 cases, 27.1%, P =0.004)were more common in the EGFR mutation group than in the wild-type group.